Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States

ConclusionsFindings from this study outline the greatest perceived barriers to adoption of biosimilars from a variety of different stakeholders. Rebates from reference product manufacturers to payers was the main deterrent for biosimilar use.

http://link.springer.com/10.1007/s40259-020-00463-6

Source: BioDrugs - January 5, 2021 Category: Drugs & Pharmacology Source Type: research